These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34990080)

  • 1. Association between vitiligo and metabolic syndrome: A systematic review and meta-analysis.
    Chuang KW; Chang HC
    J Dtsch Dermatol Ges; 2022 Feb; 20(2):218-221. PubMed ID: 34990080
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased risk of subclinical atherosclerosis and metabolic syndrome in patients with vitiligo: a real association or a coincidence?
    Namazi N; Amani M; Haghighatkhah HR; Noori E; Abdollahimajd F
    Dermatol Ther; 2021 Mar; 34(2):e14803. PubMed ID: 33496053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitiligo or Vitiligo-like Hypopigmentation Associated with Imiquimod Treatment of Condyloma Acuminatum: Not a Casual Event.
    Long FQ; Zhao LS; Qian YH
    Chin Med J (Engl); 2017 Feb; 130(4):503-504. PubMed ID: 28218231
    [No Abstract]   [Full Text] [Related]  

  • 4. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features.
    Hartmann A; Bedenk C; Keikavoussi P; Becker JC; Hamm H; Bröcker EB
    J Dtsch Dermatol Ges; 2008 Dec; 6(12):1053-9. PubMed ID: 18479500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher incidence of metabolic syndrome components in vitiligo patients: a prospective cross-sectional study.
    Tanacan E; Atakan N
    An Bras Dermatol; 2020; 95(2):165-172. PubMed ID: 32113676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Double Strike Hypothesis of the vitiligo pathomechanism: new approaches to vitiligo and melanoma.
    Michelsen D
    Med Hypotheses; 2010 Jan; 74(1):67-70. PubMed ID: 19748188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitiligo Impact Scale (VIS)-22: A measure of the psycho-social burden of vitiligo.
    Gupta V; Ramam M
    Indian J Dermatol Venereol Leprol; 2022; 88(5):691-695. PubMed ID: 35962518
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing the minimal important change in the vitiligo extent score and the self-assessment vitiligo extent score.
    Uitentuis SE; Wolkerstorfer A; Bae JM; Esmat S; Mogawer RM; Ragab N; Chuah SY; Passeron T; van Geel N; Thng STG; Terwee CB; Bekkenk MW
    J Am Acad Dermatol; 2021 Nov; 85(5):1363-1364. PubMed ID: 33122021
    [No Abstract]   [Full Text] [Related]  

  • 9. Health-related quality of life in paediatric patients with vitiligo: a systematic review and meta-analysis.
    Nathalie J; Chang J; Ezzedine K; Rodrigues M
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e755-e756. PubMed ID: 34013610
    [No Abstract]   [Full Text] [Related]  

  • 10. British Association of Dermatologists guidelines for the management of people with vitiligo 2021.
    Eleftheriadou V; Atkar R; Batchelor J; McDonald B; Novakovic L; Patel JV; Ravenscroft J; Rush E; Shah D; Shah R; Shaw L; Thompson AR; Hashme M; Exton LS; Mohd Mustapa MF; Manounah L;
    Br J Dermatol; 2022 Jan; 186(1):18-29. PubMed ID: 34160061
    [No Abstract]   [Full Text] [Related]  

  • 11. Systematic review of occupational chemical leukoderma.
    Doolan BJ; Ross G
    Int J Dermatol; 2020 Mar; 59(3):e50-e52. PubMed ID: 31743421
    [No Abstract]   [Full Text] [Related]  

  • 12. Vitiligo.
    Okoro U; Usatine RP; Heath CR
    Cutis; 2023 Feb; 111(2):106-107. PubMed ID: 37075191
    [No Abstract]   [Full Text] [Related]  

  • 13. Atypical Pattern of Choroidal Hypopigmentation with Cutaneous Vitiligo.
    Kim M; Kwon JW; Park YH
    Korean J Ophthalmol; 2019 Feb; 33(1):99-100. PubMed ID: 30746919
    [No Abstract]   [Full Text] [Related]  

  • 14. Case of vitiligo universalis as a sequela of drug-induced hypersensitivity syndrome.
    Chiang PH; Ng CY; Kuo TT; Hui RC; Chen CB; Lu CW; Chung WH
    J Dermatol; 2021 Jan; 48(1):92-95. PubMed ID: 33180345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postinflammatory hypopigmentation due to ferrous sulphate.
    Masarà A; Fabbrocini G; Cacciapuoti S; Napolitano M; Patruno C
    G Ital Dermatol Venereol; 2020 Apr; 155(2):243-244. PubMed ID: 29998708
    [No Abstract]   [Full Text] [Related]  

  • 16. Vitiligo.
    LeWitt TM; Kundu RV
    JAMA Dermatol; 2021 Sep; 157(9):1136. PubMed ID: 34287629
    [No Abstract]   [Full Text] [Related]  

  • 17. The possibility of misdiagnosis of generalized vitiligo as pigmentary disease.
    Cho YH; Lee SJ; Lee HJ; Hann SK; Lee MG; Park YK
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1364-6. PubMed ID: 17062080
    [No Abstract]   [Full Text] [Related]  

  • 18. Presentations, Signs of Activity, and Differential Diagnosis of Vitiligo.
    Goh BK; Pandya AG
    Dermatol Clin; 2017 Apr; 35(2):135-144. PubMed ID: 28317523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory vitiligo improving with eculizumab.
    Martinez-Cabriales SA; Bohdanowicz M; Wells R; Shear NH
    Dermatol Ther; 2020 Mar; 33(2):e13233. PubMed ID: 31997487
    [No Abstract]   [Full Text] [Related]  

  • 20. Neurofibromatosis and vitiligo: A simple coincidence or coexistence?
    Ouni NEI; Salah NB; Aounallah A
    Int J Rheum Dis; 2022 Apr; 25(4):506-507. PubMed ID: 35119199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.